Glycopyrrolate Sorbitol Lollipops for Drooling: Two Case Reports
Author(s): Agbi Kelechi E, Carvalho Maria, Vieira-Banov Fabiana
Issue: Nov/Dec 2021 - Volume 25, Number 6
View All Articles in Issue
Page(s): 464-467
Download in electronic PDF format for $75
Abstract: Drooling is a pathologic condition that is commonly associated with neurodisability and poor quality of life. An elderly dementia patient and an adult cancer patient suffered from persistent drooling, and they were both prescribed glycopyrrolate 0.5-mg sorbitol lollipops, per recommendation of their local compounding pharmacist. The severity and frequency of drooling decreased substantially in both patients, and there were no reported adverse effects. These two case reports demonstrate the safety and efficacy of glycopyrrolate lollipops in managing excessive salivation, as well as the importance of the triad relationship in addressing the individual patient needs.
Related Keywords: Kelechi E. Agbi, PharmD, BCGP. RPh, Maria Carvalho, PharmD, MRPharmS, PhD, Fabiana Vieira-Banov, RPh, MS, drooling, saliva, salivary secretions, hypersalivation, excessive salivation, sialorrhea, neurodisability, dementia, elderly, cancer chemotherapy, oral mucositis, swallowing disorder, antimuscarinic agents, glycopyrronium bromide, glycopyrrolate, lollipop dosage form, case reports, Drooling Severity and Frequency Scale, formulation
Related Categories: DENTAL, EAR NOSE THROAT, FORMULATIONS, GERIATRICS, CASE REPORTS, DOSAGE FORMS/DRUG CARRIERS